KR20050047579A - Bone disease drug composition using herb medicines - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing and treating bone diseases using a mixed herbal medicine, and more specifically, to prevent chronic bone disease (osteoporosis, rheumatoid arthritis) and degenerative bone by mixing a certain ratio of windproof, dew, organopi, tongchung and umbilical cord. The present invention relates to a pharmaceutical composition and health food which is very effective in preventing and treating bone diseases by inhibiting bone cell proliferation and differentiation-induced bone formation and bone tissue degradation.

Description

Bone disease drug composition using herb medicines}

The present invention relates to a pharmaceutical composition for preventing and treating bone diseases using a mixed herbal medicine, and more specifically, to prevent chronic bone disease (osteoporosis, rheumatoid arthritis) and degenerative bone by mixing a certain ratio of windproof, dew, organopi, tongchung and umbilical cord. The present invention relates to a pharmaceutical composition and health food which is very effective in preventing and treating bone diseases by inhibiting bone cell proliferation and differentiation-induced bone formation and bone tissue degradation.

Bones are not just hard tissues, but active tissues that change continuously throughout life. In the naked eye, bone is divided into external cortical bone (dense bone) and internal small bone (spongy bone, sponge bone). Cortical bone has a strong physical strength to protect and support the body, and the small bone absorbs shock Mainly plays a role in keeping calcium changes constant. Even after the bone has stopped growing, the old bone is destroyed and lost (bone absorption), and the fixation (bone formation) that fills in the place where the new bone is missing is repeated throughout life. This phenomenon is called bone remodeling. Bone resorption and bone formation must be balanced to maintain the normal shape of the bone and maintain a constant calcium concentration in the blood. When calcium is deficient in the blood, bone resorption is increased to compensate for this. If bone resorption persists, bones become weak and osteoporosis occurs.

Osteoporosis is a kind of aging phenomenon in which bone fracture is easily caused by a small impact due to a decrease in total bone mass, and it can not be avoided by anyone as it ages. It can also occur. Medically, both bone collagen and calcium are reduced and bone strength is weakened. When osteoporosis occurs, the amount of bone is reduced and fractures occur even by minor accidents. Especially, pelvic fractures and vertebral fractures are fatal in women. . When pelvic fractures occur, 30% of patients die within a year, and the probability of dying from vertebral fractures is 1.4 times higher than that of pelvic fractures, and 1.2 million women worldwide suffer from osteoporosis. Because of this seriousness, developed countries, including the United States, have made great efforts to identify the causes of osteoporosis and to develop therapeutics from early on. Many Korean scientists are currently conducting research with interest. The most important factor in determining the risk of fracture due to osteoporosis is bone density, so the measurement of bone density is very important.

Changes in bone mineral density of the bones of the small bones are lost about three times faster after menopause than in menopause, and after menopause, more than 5% is lost in a year. After menopause, the bone density of women decreases rapidly, and the difference between men and women is more severe. In men, 20-30% of the maximum bone density is lost and in women, 40-50%.

Recent developments in the treatment of osteoporosis include calcitonin injection, estrogen replacement therapy, and biphosphonate intake. Such a method is also unsatisfactory in effect, the problem of the administration method and dosage amount, side effects and the like have been a problem.

Ariad Pharmaceuticals, Inc., cambridge, Mass., USA, is a researcher working on oral medications that inhibit osteoporosis signaling. Recently, Ariad Pharmaceuticals, Inc., Cambridge, Mass., USA, has developed a small molecule that binds to the Src SH2 domain.

In addition, Axys Pharmaceuticals, Inc, San Francisco, in collaboration with Merk and Co, is developing a low molecular weight substance that inhibits Catepsin K. Cathepsin K is a cysteine protease secreted by osteoblasts and is an important enzyme in osteoporosis. Inhibitors have been developed that determine the molecular stereostructure of cathepsin K and bind to the enzyme active site.

In addition, substances modifying estrogen receptor modulators are currently in Phase 2 clinical trials at Pfizer, Inc. (New York City, USA). This drug, called Droloxifene, is an improvement on raloxifene (Evista), which is important for bones. These estrogen receptor modulators also work on the bones, heart, and breast, but not on the bladder.

Osteoprotegerin (OPG), a new treatment, reconstitutes our bones into new skeletons every seven to fourteen years. However, in the case of disease or degeneration, this balance is broken and bone is more removed than is produced. Thousand Oaks, CA, USA, found two proteins responsible for bone destruction and protection. OPG protects bones, and all of these genes are present in normal mice. Becomes stronger.

In the United States, anti-bone resorption therapy is used to prevent and treat osteoporosis. Osteomark NTx serum is a reagent for diagnosing osteoporosis by osteoblasts in the United States.

Although the above treatment methods and therapeutic agents have been continuously studied, improvement of side effects such as gastrointestinal tract, liver, kidney and the like has not been satisfactory.

Therefore, there is no side effect, and there is an urgent need for the use of herbal medicines for the treatment of bone diseases including osteoporosis.

Accordingly, the present inventors have conducted a long study on herbal preparations that can be used for osteoporosis, rheumatoid arthritis, degenerative arthritis, waist and neck disc diseases, and as a result, windbreaks, dew, cucumber skin, worms and umbilical cord extracts have chronic bone disease ( Osteoporosis, rheumatoid arthritis) and degenerative bone diseases related to osteoblast proliferation and differentiation induce osteoporosis by inhibiting the formation of bone tissue by inhibiting the osteoporosis was found to be very effective in the prevention and treatment of the disease was completed.

Accordingly, an object of the present invention is to provide a pharmaceutical composition or health food for preventing and treating bone diseases, which contains a windproof, dew, agar, worms and chamomile extract as an active ingredient.

The present invention is characterized in that the pharmaceutical composition for preventing and treating bone diseases, which contains the wind-proof, hyssop, scabies, worms and chamomile extracts as active ingredients.

In addition, it includes a health food containing the extract.

Referring to the present invention in more detail as follows.

The present invention by mixing a certain ratio of wind, dew, agar, worms and gold moths by inhibiting the proliferation of bone cells associated with chronic bone diseases (osteoporosis, rheumatoid arthritis) and degenerative bone diseases, and osteogenic and differentiation of bone tissue in differentiation The present invention relates to a pharmaceutical composition which is very effective for the prevention and treatment of bone diseases.

Windproof is dried root and root stem of perennial herb, Ledebouriella seseloides WOLFF, which contains essential oil, mannitol, high glycoside, polysaccharide and organic acid. Among the essential oils contained in the wind-proof fruit, about 66 chemical components such as pinene, limonene, palmitic acid and bisabolene are separated, and coumarins have impera Imperatorin, pelletopterin, and ledebouriellol, and the polysaccharides include saposhnikovan A, B, and C. Pharmacological action is antipyretic, analgesic, anti-inflammatory action, anti-inflammatory action, anti-convulsion action, smooth muscle relaxation action, and antibacterial action. In the present invention, to maximize the effect by using the content of the windproof 10 to 20% by weight, when the content is less than 10% by weight there is a problem that the effect is insufficient, if it exceeds 20% by weight is not economical.

Achyranthis Bidentatae Radix belonging to the amaranth family is dried root of Achyranthes japonica NAKAI in Korea, and it contains olenolic saponin, steroidal inoosterone, and ecdysterone. Root from the root is called as a treatment for congestion such as hypertension, rheumatism, arthralgia, diuretics, tonic. In the study of the ingredients of herbal medicine, recently, the structure determination by separating the olenic acid gluturonide saponin from the root of the dew is a cytotoxic saponin Achyranthosides A, B and glue Acarantotosides C and D, which are turonide saponins, were separated and structured. There are various reports on the biological activity of hyaluronic acid, including anti-inflammatory, antioxidant liver protection, anti-allergic and anticancer activity. In the present invention, the effective content of the dew is 15 to 35% by weight, when less than 15% by weight is ineffective, and when it exceeds 35% by weight there is a problem that there is insufficient bleeding.

Ogapi (Acanthopanacis Cortex), belonging to the Agalaceae family, is known for its taste, bitterness, warm properties, acting on the liver, nerves, and nerves to remove customs, nourish, and clarify essence. If you wear it, it will help your body feel up, support your stomach, clear your mind, and have a good effect on the pain in your lumbar spine. Ogapi contains the agapi glycoside and lignan lycosides acantosides A, B, C, D and receptor polysaccharides that enhance immunity. The leaves have a pharmacological function with cysanosides, and the roots contain not only the ogapi glycosides but also the silrgin and coumarin glycosides. It contains Dowsterin, and contains essential oils such as methylsalicylaldehyde and tannins, pilmitnic acid, linolenic acid, vitamins A, B, and cyringareginol. Syringareginol restores abnormal levels of S-Got and S-Gpt from the liver to normal levels rapidly, prolongs animal life, and enhances the metabolism of the drug in vivo. In the present invention, the effective amount of Ogapi is 5 to 20% by weight, the effect is insufficient if less than 5% by weight, there is a problem that heat generation exceeds 20% by weight.

Eucommiae Cortex, which belongs to the genus Camellia family, is a herb that is said to protect the liver, strengthen the musculature, and to make the body lighter and less old after long eating.It contains a large amount of collagen, potassium, crystalline rubber, and gutta-percha. It is known to be effective in hypertension, polio sequelae, and habitual miscarriage. The constituents are mainly lignans and iridoids. In addition, there are erythro and threo-guaiacylglycerol, ulmopreol, and nonacosan, and pharmacological action lowers blood pressure. Antihyperlipidemia, sedative and analgesic, anti-inflammatory, reticuloendothelial phagocytic function, and diuretic effect. In the present invention, the effective content thereof is 5 to 30% by weight, the effect is insignificant if less than 5% by weight, it is not economical if it exceeds 30% by weight.

Cibotium barometz (LINNE) J. SMITH is a perennial herb with a stag beetle, and has excellent effects on the symptoms of weakness and weakness of the waist, weak legs, and weak legs and knees. It is used for low back pain, arthritis, lower limb asthenia caused by the invasion of wind, and it is impaired by renal function. Excellent effect Its components include tannins, starches and the like. It shows antibacterial hemostatic action. In the present invention, the effective content thereof is 10 to 20% by weight, the effect is insignificant when used in less than 10% by weight, it is not economical when it exceeds 20% by weight.

On the other hand, in addition to the herbal medicine may contain one or more of Gupan, Angelica, safflower, broiler, goji berry, medicinal beans, ferns, five red bones, ripening sulfur, red beans, motherwort and genus, the preferred content is 20 to 55% by weight. If the content thereof is less than 20% by weight, the effect is insignificant, and if it exceeds 55% by weight, it is not economical.

On the other hand, the herbal extracts described above by the following method, or look at in more detail the process of efficiently separating the more excellent mixed herbal extracts as follows.

The mixed herbal medicines described above are placed in water, lower alcohols (preferably methanol, ethanol, butanol), ethyl acetate, aromatic hydrocarbons or chlorinated hydrocarbons, and then hot-water filtered at 100-130 ° C. for 6-10 hours. At this time, the amount of the aqueous solution is preferably about 2 to 5 times the volume of the mixed herbal medicines.

The extract thus separated is concentrated under reduced pressure under the conditions of 40 to 60 ° C., and then heated or lyophilized to make the extract liquid.

On the other hand, the herbal ingredients may be powdered or extracted alone, respectively, to obtain extracts, and these extracts may be mixed, or the necessary herbal ingredients may be combined and extracted together.

As a result of confirming the osteoblast proliferation effect and bone density with respect to the mixed herbal medicine extract obtained above, as shown in the following examples showed an excellent effect. Therefore, the present invention can be used as a medicine or health food for preventing and treating bone diseases containing the mixed herbal medicine extract obtained by the extraction method as an active ingredient.

When prepared as a pharmaceutical, the mixed herbal extract of the present invention may be administered orally or parenterally during clinical administration and may be provided in the form of a general pharmaceutical formulation.

The mixed herbal extract of the present invention may be administered in various oral or parenteral formulations during actual clinical administration, and when formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. that are commonly used. It is prepared using.

Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose in lignans and lactone compounds and derivatives thereof. Mixed with gelatin. In addition to simple excipients, lubricants such as magnesium straight and talc are also used. Liquid preparations for oral administration include suspensions, solvents, emulsions, and syrups. In addition to the commonly used simple diluents, water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have.

Formulations for parenteral administration include sterile aqueous solutions, water-insoluble solvents, suspensions, emulsions, lyophilizers, suppositories. As the non-aqueous and suspending solvent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used. As the base of the suppository, utopsol, macrogol, tween 61, cacao butter, laurin butter, glycerol gelatin and the like can be used.

The content in the preparation of the active ingredient according to the present invention can be appropriately selected depending on the absorbency, inactivation rate, excretion rate, age, sex and condition of the user in the body. In the case of the mixed herbal medicine extract of the present invention, it is 3000 to 6000 mg / kg, preferably 4000 to 5000 mg / kg, and can be administered 1 to 3 times a day.

In addition, the present invention prevents bone disease by inhibiting bone formation and bone tissue degradation in osteoblast proliferation and differentiation in association with chronic bone disease (osteoporosis, rheumatoid arthritis) and degenerative bone disease as an active ingredient mixed herbal medicines Contains health foods that are very effective in treatment.

The health food is a food prepared by adding the mixed herbal medicine extract to a general food, or capsules, powdered, suspensions, etc., and when ingesting it, has a specific effect on health, but unlike a general medicine It has the advantage that there is no side effect that can occur during long-term use of the drug as a raw material.

Hereinafter, the present invention will be described in more detail based on the following examples, but the present invention is not limited thereto.

Example 1

Windproof 150 g, 200 g of dew, 150 g of Ogapi, 300 g of Tobacco, 200 g of Geumgucheokgi were mixed in distilled water (or purified water) in a volume of 2 to 5 times, heated under reflux for 8 hours, and filtered to prepare a filtrate. The resultant was concentrated under reduced pressure to 100 ml and lyophilized to obtain a freeze-dried weight of about 150 g.

Example 2

Wind-proof 100 g, 200 g of dew, 100 g of Ogapi, 100 g of Tofu, 100 g of Jingu gukcheok, 50 g of old plate, 150 g of Angelica, and 200 g of safflower were extracted with water in the same manner as in Example 1 to obtain an extract.

Example 3

Windproof 100 g, 150 g of dew, 50 g of Ogapi, 50 g of Tofu, 100 g of broiled chicken, 100 g of broiler, 50 g of wolfberry, 50 g of medicinal beans, 100 g of fern, 300 g of safflower with water in the same manner as in Example 1 above It extracted and obtained the extract.

Example 4

Wind-proof 150 g, 250 g of dew, 100 g of Ogapi, 100 g of Tofu, 200 g of Gold Mochumcheok, 100 g of Ohjeolgol and 100 g of Gobi were extracted in the same manner as in Example 1 to obtain an extract.

Example 5

Wind 150g, dew 250g, 100g of Ogapi, 50g of Tofu, 200g of Jingu gukcheok, 50g of old plate, 50g of sucrose and red ginseng were extracted with water in the same manner as in Example 1 to obtain an extract.

Example 6

Windproof 100 g, dew 150 g, Ogapi 200 g, tofu 100 g, Jingu Gucheok 200 g, safflower 200 g, Sukji sulfur 50 g was extracted with water in the same manner as in Example 1 to extract.

Example 7

Windproof 150 g, 150 g of dew, 100 g of Ogapi, 200 g of Tofu, 100 g of Goldfish guchu 100 g, Gobi 50 g, motherwort vinegar 50 g, genus 50 g, 50 g of sucrose and sulfur extract in the same manner as in Example 1 It was.

Experimental Example 1: Osteoblast proliferation assay

1) Cell Culture of Osteoblasts

The MG-63 cell line and HOS-TE85 cell line, which had similar properties to osteoblasts, a component of bone, were distributed from the Korea Cell Line Bank of Seoul National University College of Medicine.

MG-63 used DMEM medium [Gibco BRL, USA] containing 10% FBS, penicillin 100 U / ml, streptomycin 100 [mu] g / ml, and HOS-TE85 cell line was subjected to wet conditions using 37 Incubation was carried out in an incubator containing 5% CO ₂ at ° C. The medium was changed three times a week and subcultured once a week.

2) cell proliferation experiment according to the extract concentration; MTT Experiment

The MG-63 and HOS-TE85 cell lines cultured in 1) were inoculated into 96 well plates, and the mixed herbal extract of the present invention was added to 6 wells at each concentration so as to have a concentration of 1 μg / ml per dry medicine. As a control, no extract was added, and as a comparison group in the MG-63 cell line and the HOS-TE85 cell line, Livial, which is currently mainly used as a therapeutic agent for osteoporosis, was used.

The cell line was incubated for 3 days in an incubator at 37 ° C., and MTT (3- (4,5-dimethylthiazol-2-YL) -2,5-diphenyltetrazolium bromid; Triazoly Blue) was added at a concentration of 0.05 mg / ml. Incubated further 4 hours under conditions. The resulting formazan crystals were dissolved in DMSO and absorbance at 550 nm was measured with an ELISA reader.

Cell growth rate (%) was calculated as the ratio (%) of absorbance of the extract added wells to the absorbance of the control wells without the extract.

As a result, the mixed herbal extract of the present invention showed an excellent proliferation rate for osteoblast-like cells such as MG-63 [Fig. 1]. It was confirmed that osteoblast proliferation rate was superior to that of Rivial, which is conventionally used as a treatment for osteoporosis [FIG. 2]. In addition, the mixed herbal extract of the present invention showed excellent proliferation rate for osteoblast-like cells such as HOS-TE85. Therefore, it was confirmed that the mixed herbal extract of the present invention can be usefully used for drugs and health foods related to the treatment or prevention of osteoporosis.

As a result of examining the effect of the mixed herbal medicine extract of the present invention on the proliferation of osteoblasts, it was confirmed that there is an excellent proliferative effect on the osteoblasts. In addition, the osteoblast proliferation rate was higher than that of the rivial, which is conventionally used as a therapeutic agent for osteoporosis.

Experimental Example 2: Animal Experiment of Osteoporosis Model Animal Experiment on Ovariectomized Rat

In order to observe the inhibitory effect of osteoporosis, SD (Sprague-Dawley) female rats undergoing postmenopausal type I osteoporosis were examined for ovarian extraction and the changes in the area of the minor bone were measured. As a test material, 10-week-old female rats having a body weight of 200-220 g were subjected to bilateral ovarian extraction. The normal group was a group that performed all operations except ovarian extraction. The control group was not administered the extract of Example 1 above. , The administration group was raised for 10 weeks by oral administration of 3000 mg / kg once a day extract of Example 1.

1) Measurement of changes in body weight and tissue weight by drug administration

After the ovary was extracted by the above method, the weight of the experimental animal to which the drug was administered was measured weekly, and the tissue weight was measured after a certain period of time to extract the normal group and the ovaries which performed all operations except ovarian extraction. (boneferroni multiple comparison method) was compared with the weight and tissue weight of the control group not administered drug [Table 1].

As a result, there was no difference in body weight and tissue weight when compared with the control group. That is, it is considered that there is no hormonal change that is large enough to show a change in body weight or tissue weight, so the extract of the present invention is considered to be a safe drug.

Changes in Body Weight of Laboratory Animals by Drug Administration Classification (week) Control Normal Mixed Herbal Extract Administration Group 10 204.1 ± 3.42 204.3 ± 3.56 203.2 ± 4.23 11 224.6 ± 4.21 212.6 ± 6.23 234.9 ± 3.87 ^* 12 234.8 ± 5.64 ^** 228.8 ± 2.78 236.8 ± 4.236 13 244.9 ± 6.45 249.9 ± 1.23 ^* 249.9 ± 2.46 14 257.7 ± 7.26 251.7 ± 4.72 253.7 ± 4.33 ^** 15 275.8 ± 6.45 279.4 ± 4.98 ^* 268.8 ± 5.89 16 267.4 ± 1.32 ^** 287.4 ± 3.45 272.4 ± 8.41 17 289.9 ± 4.78 287.3 ± 5.119 289.2 ± 3.50 18 291.3 ± 4.57 ^** 294.3 ± 8.24 298.4 ± 9.78 ^** 19 319.4 ± 8.72 316.8 ± 6.27 ^** 322.4 ± 6.57 20 314.1 ± 5.49 324.7 ± 8.67 327.3 ± 6.42 ^{* *} : P <0.05, ^** : P <0.01 compared to 10 weeks of age

2) Histopathological observation

The collected femoral bone tissue was demineralized in aqueous formic acid os fixed in 10% formarin solution. Observation sites of bone tissue were cut with a surgical knife, washed with xylene, and paraffin embedded through dehydration processes ranging from 20 to 100% alcohol and acetone. Paraffin-embedded bone tissue was cut to 5 μm with micron, hematoxylin and eosin (H & E) staining and gomori staining were performed, and confirmed with an optical microscope [FIG. 3].

3) Morphometric Analysis

Each group was subjected to morphometric analysis in the tibia by the following method. Using the meta-view program in the optical microscope, the area of each trabecular in the tibia was automatically calculated, and the area of the minor bone was obtained from this. In the proximal tibia of each of the number of the following average area of the length of the straight portion of the lower portion of the growth plate obtained for the number of roadside inside the reference area ² × 10 ⁶ ㎛ 2 to a length of about 2/3 of the growth plate length rectangular trabeculae By multiplying the small bone area of each bone sample was statistically processed [Fig. 4].

As a result, the control group extracted from the ovary was reduced by 82% of the area of the subcetabular bone compared to the normal group, indicating that osteoporosis was induced. In addition, the area of osseous bone due to ovarian extraction was increased by the administration of mixed herbal extract, which was lower than the normal group ( ^* ; p <0.05, ^** p <0.01), but significantly increased compared to the control group.

Administration of the mixed herbal medicine extract of the present invention increased the area of the small bones by about 89.8% compared to the control group. Therefore, it can be seen that the mixed herbal medicine extract of the present invention can be effectively used for the prevention and treatment of osteoporosis.

Experimental Example 3: Oral Acute Toxicity in Rats

Acute toxicity test was performed using 8-week-old specific pathogen-free (SPF) SD rats. In five rats per group, the mixed herbal medicine extract of the present invention was suspended in 0.5% methylcellulose solution and administered once orally at a dose of 1 g / kg / mL. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed, blood tests and blood biochemical tests were performed, and necropsy was performed to observe abdominal and thoracic organ abnormalities.

As a result, there were no clinical symptoms or deaths in all animals treated with the test substance, and no toxicity change was observed in weight change, blood test, blood biochemistry test, autopsy findings (LD ₅₀ 9000 mg / kg). More than)

Experimental Example 4 Measurement of Bone Mineral Density and Bone Content of Tibia

After 10 weeks of breeding, bone mineral denxity (BMD) and bone mineral contents (BMC) of tibia were measured using PIXIMUS, Lunar's rat BMD. The unit of bone content is expressed in g, and the bone density is expressed in g / cm ² [Table 2]. The bone mineral density and bone mineral content of the tibia of the extract-administered group of the present invention is 0.307375 (g) and bone density is 0.183838 (g / cm ² ) as the bone mineral content 0.263818 (g) and bone density 0.175891 (g / cm) of the control group. ² ) tended to be higher than that. The tibial bone density divided by weight is 0.727961 (g / cm ² ) in the control group, the tibial bone density divided by the weight of the extract-administered group of the present invention is 0.800333 (g / cm ² ) as high as the extract administration group of the present invention increases bone density It was found to be effective.

division BMD (g / cm ² ) BMC (g) BMD / wt Normal 0.20365 0.3165 0.866596 Control 0.175891 0.263818 0.727962 Mixed Herbal Extract Administration Group 0.183838 0.307375 0.800333

Preparation Example 1 Preparation of Powder and Capsule

10 mg of the mixed herbal extract of the present invention was mixed with 14.8 mg of lactose, 3 mg of crystalline cellulose, and 0.2 mg of magnesium stearate. The mixture was filled into No. 5 gelatin capsules using a suitable apparatus.

The components of the powder and the capsules are as follows.

Mixed Herbal Extracts ·········· 10 mg

Lactose ····················· 14.8 mg

Crystalline cellulose 3 mg

Magnesium Stearate 0.2 mg

Preparation Example 2 Preparation of Injection Solution

10 mg of the mixed herbal extract of the present invention, mannitol 180 mg, Na ₂ HPO ₄ 12H ₂ O 26 mg and distilled water 2974 mg was prepared to inject. The solution was placed in a bottle and heated at 20 ° C. for 30 minutes for sterilization.

Mixed medicinal herb extract ············· 10 mg

Mannitol 180mg

Na ₂ HPO ₄ 12H ₂ O 26 mg

Distilled water ················· 2974 mg

Preparation Example 3 Preparation of Health Food (Tablet, Capsule or Beverage)

It was prepared by mixing 0.2 g of the mixed herbal extract of the present invention, powdered vitamin E, iron lactate, zinc oxide, nicotinic acid amide, vitamin A, vitamin B1 and vitamin B2 on a daily dose basis.

The components of the health food is as follows (per person daily dose basis).

Mixed medicinal herb extract ········· 300 mg

Ginseng Extract ·················· 100 mg

Green Tea Extract ················ 100 mg

100 mg of vitamin C ·················

Powdered Vitamin E 120 mg

Iron Lactate ... 2 mg

Zinc Oxide ················ 2 mg

Nicotinamide ... 20 mg

Vitamin A ... 5 mg

Vitamin B1 2 mg

Vitamin B2 · 2 mg ··········

Corn starch ... 200 mg

Magnesium stearate 20 mg

As described above, the mixed herbal medicine extract according to the present invention has been shown to increase osteoblasts, increase bone density in experimental animal groups, and increase the area of small intestinal bone, thereby preventing bone diseases such as arthritis, osteoporosis, and distress. And very useful for treatment. In addition, since it is not toxic at all, it can be widely used as a dietary supplement.

Figure 1 shows the effect of cell proliferation in the female cell line HOS-TE85 (a) and male cell line MG-63 (b) similar to osteoblasts through the mixed herbal extract of the present invention.

Figure 2 shows the results of comparing the osteoblast proliferation rate of the mixed herbal medicine extract of the present invention and conventional osteoporosis therapeutics.

3 is a tibial photograph (A) of the normal group administered orally with oriental water for 10 weeks instead of the mixed herbal medicine extract of the present invention, the tibial photograph (B) of the control group not administered the mixed herbal medicine extract of the present invention, the mixture of the present invention The tibia picture (C) of the group orally administered the herbal extract for 10 weeks is shown.

Figure 4 shows a comparative graph of each group of the sub-catheter bone area of the rat tibia orally administered 10 minutes of the mixed herbal medicine extract of the present invention.

Claims (5)

Wind-proof, dew, scabies, tofu and extracts of gold moth extract as an active ingredient, the pharmaceutical composition for preventing and treating bone diseases. The pharmaceutical composition according to claim 1, wherein the extract further comprises at least one extract selected from gupan, donkey, safflower, broiler, wolfberry, medicinal beans, ferns, five red bones, sage lees, red beans, motherwort and genus. According to claim 1, wherein the extract is windproof 10 to 20% by weight, 15 to 35% by weight of wort, 5 to 20% by weight of Ogapi, 5 to 30% by weight of larvae and 10 to 20% by weight of gold moth extract. Composition. Health food, characterized in that it contains the main components of the windproof, hyssop, scabies, tofu and goldfish guchu. The health food according to claim 4, wherein the extract further comprises one or more extracts selected from gupan, donkey, safflower, broiler, wolfberry, medicinal beans, ferns, five red bones, sorghum, red beans, motherwort and genus.